Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

(2018) Aneel Paulus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Diagnosis and Management of Waldenström Macroglobulinemia

(2017) Prashant Kapoor et al.   JAMA Oncology

Preclinical models of Waldenström's macroglobulinemia and drug resistance

(2016) Sikander Ailawadhi et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Novel therapeutic targets in Waldenstrom macroglobulinemia

(2016) Aneel Paulus et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model

(2016) Ajaz Ahmad et al.   MOLECULAR PHARMACEUTICS

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

(2016) A Paulus et al.   Blood Cancer Journal

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells

(2015) Kasyapa Chitta et al.   BRITISH JOURNAL OF HAEMATOLOGY

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance

(2015) Alak Manna et al.   PHYTOMEDICINE

Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia

(2014) K Chitta et al.   Blood Cancer Journal

The ubiquitin proteasome system — Implications for cell cycle control and the targeted treatment of cancer

(2013) Florian Bassermann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy

(2013) Tiffany DeVine et al.   CURRENT PHARMACEUTICAL DESIGN

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenström Macroglobulinemia 1

(2012) Kasyapa S. Chitta et al.   LEUKEMIA & LYMPHOMA

General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma

(2012) Annemiek Broyl et al.   SEMINARS IN HEMATOLOGY

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma

(2010) Linhua Jin et al.   CANCER LETTERS

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

(2009) M. G. Ooi et al.   CLINICAL CANCER RESEARCH

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

(2009) M. Miyachi et al.   CLINICAL CANCER RESEARCH

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors

(2008) S. Sharma et al.   BLOOD